摘要
目的:观察痰热清联合莫西沙星治疗慢性阻塞性肺疾病(COPD)合并肺部感染患者的效果。方法:选取2021年5月至2023年4月该院收治的96例COPD合并肺部感染患者进行前瞻性研究,按照随机数字表法将其分为研究组和对照组各48例。对照组采用莫西沙星治疗,研究组在对照组基础上联合痰热清注射液治疗,比较两组临床疗效,治疗前后炎性因子[C反应蛋白(CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)]水平、肺功能指标[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)]水平、T细胞亚群指标(CD3^(+)、CD4^(+)、CD8^(+))水平,以及不良反应发生率。结果:研究组治疗总有效率为91.67%(44/48),高于对照组的77.08%(37/48),差异有统计学意义(P<0.05);治疗后,两组PCT、CRP、IL-6水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组FEV_(1)、FVC水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);两组CD3^(+)、CD4^(+)水平均高于治疗前,且研究组高+于对照组,两组CD8水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:痰热清注射液联合莫西沙星治疗COPD合并肺部感染患者可提高临床疗效和肺功能指标水平,改善T细胞亚群指标水平,降低炎性因子水平,其效果优于单纯莫西沙星治疗。
Objective:To observe effects of Tanreqing combined with Moxifloxacin in treatment of patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary infection.Methods:A prospective study was conducted on 96 patients with COPD complicated with pulmonary infection admitted to the hospital from May 2021 to April 2023.According to the random number table method,they were divided into study group and control group,48 cases in each group.The control group was treated with Moxifloxacin,while the study group was treated with Tanreqing injection on the basis of that of the control group.The clinical efficacy,the levels of inflammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),procalcitonin(PCT)],lung function indexes[forced expiratory volume in the first second(FEV_(1)),forced vital capacity(FVC)]and T cell subsets indexes(CD3^(+),CD4^(+),CD8^(+))before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 91.67%(44/48),which was higher than 77.08%(37/48)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PCT,CRP and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of FEV_(1)and FVC in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences++were statistically significant(P<0.05).After the treatment,the levels of CD3^(+) and CD4^(+) in the two groups were higher than those before the treatment,and those+in the study group were higher than those in the control group;the levels of CD8^(+) in the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tanreqing injection combined with Moxifloxacin in the treatment of the COPD patients with pulmonary infection can improve the therapeutic effects and the levels of pulmonary function indexes,improve the levels of T cell subsets and reduce the levels of inflammatory factors.Moreover,it is superior to simple Moxifloxacin treatment.
作者
张南
张金献
杨素素
ZHANG Nan;ZHANG Jinxian;YANG Susu(Second Ward of Respiratory and Critical Care Department of Pingdingshan Hewu General Hospital,Pingdingshan 462500 Henan,China)
出处
《中国民康医学》
2024年第16期94-97,共4页
Medical Journal of Chinese People’s Health
关键词
痰热清
莫西沙星
慢性阻塞性肺疾病
肺部感染
肺功能
炎性因子
T细胞亚群
Tanreqing
Moxifloxacin
Chronic obstructive pulmonary disease
Pulmonary infection
Lung function
Inflammatory factor
T cell subset
